Thouvenin Jonathan, Masson Claire, Boudier Philippe, Maillet Denis, Kuchler-Bopp Sabine, Barthélémy Philippe, Massfelder Thierry
Medical Oncology Department, Hospices Civils de Lyon, Hôpital Lyon Sud, 69310 Pierre-Bénite, France.
Regenerative NanoMedicine, Centre de Recherche en Biomédecine de Strasbourg, Fédération de Médecine Translationnelle de Strasbourg (FMTS), UMR_S U1260 INSERM, University of Strasbourg, 67085 Strasbourg, France.
Cancers (Basel). 2023 Jan 27;15(3):793. doi: 10.3390/cancers15030793.
Renal-cell carcinoma (RCC) accounts for 2% of cancer diagnoses and deaths worldwide. Clear-cell RCCs represent the vast majority (85%) of kidney cancers and are considered morphologically and genetically as immunogenic tumors. Indeed, the RCC tumoral microenvironment comprises T cells and myeloid cells in an immunosuppressive state, providing an opportunity to restore their activity through immunotherapy. Standard first-line systemic treatment for metastatic patients includes immune-checkpoint inhibitors (ICIs) targeting PD1, in combination with either another ICI or with antiangiogenic targeted therapy. During the past few years, several combinations have been approved with an overall survival benefit and overall response rate that depend on the combination. Interestingly, some patients achieve prolonged complete responses, raising the question of whether these metastatic RCC patients can be cured. This review will focus on recent therapeutic advances in RCC and the clinical and biological aspects underpinning the potential for healing.
肾细胞癌（RCC）占全球癌症诊断和死亡病例的2%。透明细胞RCC占肾癌的绝大多数（85%），在形态学和遗传学上被认为是免疫原性肿瘤。实际上，RCC肿瘤微环境包含处于免疫抑制状态的T细胞和髓样细胞，这为通过免疫疗法恢复它们的活性提供了机会。转移性患者的标准一线全身治疗包括靶向PD1的免疫检查点抑制剂（ICIs），可与另一种ICIs或抗血管生成靶向治疗联合使用。在过去几年中，几种联合治疗方案已获批，其总生存获益和总缓解率取决于联合方案。有趣的是，一些患者实现了长期完全缓解，这就提出了这些转移性RCC患者是否能够治愈的问题。本综述将聚焦于RCC的近期治疗进展以及支持治愈可能性的临床和生物学方面。
